Themis Medicare Ltd
Themis Medicare Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹72Cr
- −26.7% YoY
- Net profit
- −₹10Cr
- Q4 FY24: ₹7 Cr
- Margin
- −10.74%
- −20.2 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY25 Net Revenue: Rs. 71.70 Cr, down 27% YoY from Rs. 97.82 Cr in Q4 FY24 (Page 8). Q4 FY25 EBITDA: -₹5.78 Cr, down 162% YoY vs.
From Themis Medicare Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Net Revenue: Rs. 71.70 Cr, down 27% YoY from Rs. 97.82 Cr in Q4 FY24 (Page 8).
- Formulation Segment grew 20.41% YoY for FY25 (Page 8).
- Hospital and Trade business revenue grew over 11% and ~39% respectively YoY for FY25 (Page 8).
- API business showed a strong recovery in Q4 FY25 with 115% quarter-on-quarter growth compared to Q3 FY25 (Page 8).
- FY25 full year Net Revenue: Rs. 405.51 Cr, up 6.22% YoY from Rs. 381.76 Cr in FY24 (Page 9).
- The company aspires to grow CAGR of 35% over next 3 years (Page 18).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 72 | 98 | -26.7% | 94 | -23.6% |
| Operating profit (EBITDA) | -8 | 9 | -182.9% | 6 | -229% |
| Operating margin | -10.74% | 9.5% | -20.2 pp | 6.36% | -17.1 pp |
| Profit before tax | -11 | 9 | -227.3% | 2 | -770.5% |
| Net profit (PAT) | -10 | 7 | -245.5% | 1 | -1957.7% |
| EPS (₹) | -1.05 | 0.72 | -245.8% | 0.06 | -1850% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
- Kopran (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key concall takeaways from Kopran Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q4 FY25 results?
Q4 FY25 Net Revenue: Rs. 71.70 Cr, down 27% YoY from Rs. 97.82 Cr in Q4 FY24 (Page 8). Q4 FY25 EBITDA: -₹5.78 Cr, down 162% YoY vs.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.